Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
SRPT on Nasdaq
Shares outstanding
105,632,895
Price per share
$21.52
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
86,806,847
Total reported value
$1,674,704,335
% of total 13F portfolios
0%
Share change
+3,417,529
Value change
+$92,781,934
Number of holders
310
Price from insider filings
$21.52
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 11% $213,473,164 10,641,733 The Vanguard Group 29 Aug 2025
STATE STREET CORP 5.4% $102,225,558 5,304,907 STATE STREET CORPORATION 30 Sep 2025
D. E. SHAW & CO, L.P. 1.9% -64% $38,675,372 -$58,829,132 2,007,025 -60% D. E. Shaw & Co., L.P. 30 Sep 2025
Capital International Investors 0.5% -98% $10,514,369 -$167,943,865 524,146 -94% Capital International Investors 30 Jun 2025
As of 30 Sep 2025, Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT) has 310 institutional shareholders filing 13F forms. They hold 86,806,847 shares. of 105,632,895 outstanding shares (82%) .

Top 25 institutional shareholders own 61% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 12% 13,199,845 +9% 0% $254,361,023
VANGUARD GROUP INC 10% 10,817,446 +18% 0% $208,452,185
STATE STREET CORP 5% 5,304,907 +13% 0% $102,225,558
Erste Asset Management GmbH 2.5% 2,685,945 +66% 0.49% $50,588,160
RENAISSANCE TECHNOLOGIES LLC 2.5% 2,650,178 +324% 0.07% $51,068,930
TWO SIGMA INVESTMENTS, LP 2% 2,137,764 -1.1% 0.06% $41,194,712
D. E. Shaw & Co., Inc. 1.9% 2,007,025 -55% 0.03% $38,675,372
UBS Group AG 1.9% 1,990,508 +297% 0.01% $38,357,088
Aberdeen Group plc 1.9% 1,982,764 +60% 0.06% $38,207,862
TWO SIGMA ADVISERS, LP 1.9% 1,958,034 -1.4% 0.08% $37,731,315
MORGAN STANLEY 1.8% 1,948,358 +31% 0% $37,544,863
FIRST TRUST ADVISORS LP 1.8% 1,939,781 +209% 0.03% $37,379,579
BNP PARIBAS FINANCIAL MARKETS 1.7% 1,781,348 0% 0.03% $34,326,576
Connor, Clark & Lunn Investment Management Ltd. 1.7% 1,745,051 +184% 0.11% $33,627,133
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,721,124 -8.3% 0% $33,172,867
AQR CAPITAL MANAGEMENT LLC 1.3% 1,405,675 +1016% 0.02% $26,398,577
T. Rowe Price Investment Management, Inc. 1.3% 1,366,690 +188% 0.02% $26,337,000
VOLORIDGE INVESTMENT MANAGEMENT, LLC 1.2% 1,308,738 -11% 0.08% $25,219,381
FEDERATED HERMES, INC. 1.2% 1,308,691 +0.04% 0.04% $25,218,476
CITIGROUP INC 0.96% 1,018,922 +384% 0.01% $19,634,627
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.94% 990,866 +450% 0.03% $19,093,988
683 Capital Management, LLC 0.94% 990,000 +47% 1.7% $19,077,300
Amundi 0.92% 969,826 +378% 0.01% $22,558,153
Invesco Ltd. 0.79% 832,638 +242% 0% $16,044,935
BRAIDWELL LP 0.79% 832,100 0.48% $16,034,567

Institutional Holders of Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 386,327 $8,417,225 -$5,757,144 $21.52 10
2025 Q3 86,806,847 $1,674,704,335 +$92,781,934 $19.27 310
2025 Q2 82,768,888 $1,414,059,003 -$616,173,073 $17.10 354
2025 Q1 85,642,222 $5,481,981,860 -$371,507,742 $63.82 418
2024 Q4 87,836,766 $10,681,247,146 +$238,081,360 $121.59 457
2024 Q3 85,780,233 $10,708,084,374 -$609,293,520 $124.89 454
2024 Q2 88,781,079 $14,026,528,442 +$1,077,191,902 $158.00 484
2024 Q1 81,872,508 $10,595,217,482 +$176,716,124 $129.46 413
2023 Q4 1,087,389 $104,912,812 +$6,736,368 $96.43 4
2023 Q3 79,200,750 $9,599,300,775 +$172,452,913 $121.22 386
2023 Q2 80,116,283 $9,175,967,107 -$53,938,576 $114.52 394
2023 Q1 76,797,215 $10,583,306,253 -$58,781,052 $137.83 415
2022 Q4 78,207,250 $10,133,592,045 +$85,808,953 $129.58 400
2022 Q3 77,450,966 $8,561,346,651 +$599,287,042 $110.54 357
2022 Q2 71,632,507 $5,369,546,681 +$109,083,759 $74.96 305
2022 Q1 72,196,449 $5,641,181,260 +$61,510,309 $78.12 310
2021 Q4 70,926,754 $6,386,977,111 +$536,253,954 $90.05 319
2021 Q3 64,874,151 $5,998,661,312 +$135,435,592 $92.48 295
2021 Q2 63,954,513 $4,971,376,992 -$93,904,778 $77.74 315
2021 Q1 65,515,285 $4,880,560,789 -$732,202,425 $74.53 342
2020 Q4 70,163,751 $11,957,661,998 -$165,824,017 $170.49 424
2020 Q3 71,691,745 $10,065,659,137 -$330,120,277 $140.43 389
2020 Q2 73,461,849 $11,779,494,042 +$154,226,576 $160.34 395
2020 Q1 72,672,926 $7,107,026,998 -$31,712,566 $97.82 338
2019 Q4 72,890,896 $9,404,213,953 -$5,607,244 $129.04 374
2019 Q3 72,640,632 $5,470,966,668 -$253,416,444 $75.32 325
2019 Q2 71,173,242 $10,810,530,356 +$369,371,451 $151.95 354
2019 Q1 70,481,575 $8,408,803,348 +$282,630,138 $119.19 355
2018 Q4 68,147,068 $7,437,079,479 +$732,785,812 $109.13 322
2018 Q3 60,070,086 $9,700,214,828 +$262,064,132 $161.51 333
2018 Q2 59,822,826 $7,907,294,334 +$568,836,713 $132.18 307
2018 Q1 56,354,518 $4,173,671,314 +$183,614,577 $74.09 262
2017 Q4 55,205,992 $3,072,284,494 +$54,900,721 $55.64 245
2017 Q3 53,669,021 $2,438,844,342 +$525,340,593 $45.36 225
2017 Q2 42,614,641 $1,436,209,836 +$82,229,855 $33.71 182
2017 Q1 40,723,946 $1,205,275,294 +$218,795,753 $29.60 174
2016 Q4 39,367,659 $1,079,911,087 -$168,105,816 $27.43 174
2016 Q3 42,402,505 $2,599,865,264 +$579,270,225 $61.41 182
2016 Q2 34,630,592 $660,414,393 -$12,882,656 $19.07 142
2016 Q1 34,884,647 $680,875,808 +$86,256,980 $19.52 128
2015 Q4 28,532,796 $1,100,883,608 +$34,764,631 $38.58 146
2015 Q3 27,763,007 $891,448,724 +$36,267,512 $32.11 144
2015 Q2 26,208,106 $797,493,439 +$87,087,286 $30.43 125
2015 Q1 24,179,978 $320,899,632 -$7,611,697 $13.28 112
2014 Q4 24,496,345 $354,077,111 -$43,772,381 $14.47 117
2014 Q3 25,967,938 $547,925,873 -$18,870,294 $21.10 121
2014 Q2 26,637,627 $793,548,050 +$16,337,238 $29.79 125
2014 Q1 26,596,410 $639,243,096 -$12,220,481 $24.03 114